Research programme: Regulatory T cell therapy - KSQ Therapeutics
Latest Information Update: 02 Sep 2023
At a glance
- Originator KSQ Therapeutics
- Class Gene therapies; Immunotherapies; Regulatory T lymphocyte cell therapies; T lymphocyte cell therapies
- Mechanism of Action Immunomodulators; Regulatory T-lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Autoimmune disorders
Most Recent Events
- 25 Apr 2023 Early research in Autoimmune disorders in USA (unspecified route) (KSQ Therapeutics pipeline, April 2023)